Immunax

Neurological Disorders

Immunax Supports Brain and Nervous System Health

Neurological disorders include neurodegenerative and neurodevelopmental diseases that affect the central nervous system (CNS). In other words, diseases of the brain, spinal cord, nerves, neuromuscular junctions, muscles, and the autonomic nervous system. They include conditions such as:

Alzheimer's disease

Parkinson's disease

Multiple sclerosis (MS)

Autism spectrum disorders (ASD)

Amyotrophic lateral sclerosis (ALS)

Chronic fatigue syndrome (CFS)

Scientific research has explored the potential benefits of VDBP-MAF supplementation in these debilitating conditions, which can have a major impact on quality of life.

How Does It Work?

Studies suggest that the effects of Immunax on neurological disorders may involve various mechanisms, including immune system modulation, direct effects on neurons and neurogenesis, and the interconnection between VDBP-MAF and Vitamin D Receptor (VDR) signaling pathways [3] [11]. VDBP-MAF has also been shown to modulate gene expression in the endocannabinoid system and help to regulate the immune system [12].

Critical neural macrophages are called microglia. Microglia are the resident innate immune cells of the central nervous system. They support the immune system by defending against invasive threats and initiating repair mechanisms of the nervous system. Microglia are especially prevalent during the development and rewiring of the brain. Their function is considered an essential part of the rebuilding of the human brain and nervous system.

As an immune-modulating Macrophage Activating Protein (iMAP), Immunax helps to regulate microglial activity. It can also help to modulate certain inflammatory cytokines such as TNF-α, which have been linked to various neurological conditions [17]. Furthermore, VDBP-MAF enables microglia to perform scavenging activity and clear cellular debris without inducing neurological inflammation.

Further studies are necessary to fully define the working mechanisms of Immunax and how it modulates microglial activity in patients with neurological conditions. However, reported clinical benefits are highly promising.

Potential Indications of Immunax

Multiple Sclerosis (MS)

Multiple sclerosis (MS) is an autoimmune neurological disease characterized by inflammatory and demyelinating degeneration of the central nervous system. TNF-α contributes to a variety of neurological pathologies including MS [17]. Immunax has shown promise in modulating the immune system, regulating TNF-α production, and restoring immune balance in patients with MS, leading to rehabilitation, improvements in mobility, and increased overall well-being as reported in certain case studies [15].

Alzheimer's and Parkinson's Disease

In Alzheimer’s and Parkinson’s disease, VDBP-MAF therapy has demonstrated benefits by inhibiting the overproduction of the protein TNF-α, which promotes neuron death and disrupts synaptic communication [13] [17]. By modulating microglial activity and occupying TNF-α receptors, Immunax may help to prevent neuronal death, alleviate symptoms of neurodegenerative diseases, and stimulate repair and regeneration processes [18]. However, continuous treatment may be necessary to maintain the positive effects and prevent disease progression [13].

Chronic Fatigue Syndrome (CFS)

Chronic fatigue syndrome (CFS) is a complex neurological condition characterized by long-term fatigue and reduced ability to carry out daily activities. VDBP-MAF has shown potential in reactivating the immune system and improving the condition of CFS patients, leading to partial recovery and an improvement in symptoms [11] [16] [29]. Immune system dysfunction and elevated nagalase levels have been associated with CFS. iMAP therapy with Immunax has shown promise in improving symptoms by reducing nagalase activity and activating macrophages. VDBP-MAF supplementation may help to restore immune function and alleviate the debilitating fatigue experienced by individuals with CFS.

Amyotrophic Lateral Sclerosis (ALS, Lou-Gehrig-Syndrom, Charcot-disease)

Amyotrophic lateral sclerosis (ALS) is considered to be an autoimmune disorder that results in the degeneration of motor neurons in the central nervous system (CNS), leading to muscle weakness, paralysis, and eventually respiratory failure. Vitamin D, Vitamin D Binding Protein (VDBP) and Vitamin D binding Protein Macrophage Activating Factor (VDBP-MAF) can act as a potent immune modulators. Studies have shown that replacement therapy with a stabilized Vitamin D protein complex including Vitamin D3, VDBP and VDBP-MAF provided beneficial responses, especially improvement of motor dysfunction [16] [20]. Oxidative stress, Vitamin D, VDBP and VDBP-MAF have been highlighted by researchers as playing a key role in the onset and development of ALS [20].

Autism Spectrum Disorders (ASD)

Autism spectrum disorders are neurodevelopmental conditions associated with immune system dysregulation. VDBP-MAF replacement therapy has been investigated for ASD and has been shown to decrease the activity of cannabinoid receptor type 2 (CB2R) and reactivate macrophages [12]. Promising results have been reported after treatment with VDBP-MAF, with significant improvements and even full recovery observed in some cases [13].

Other studies have examined nagalase activity in individuals with ASD and the effects of VDBP-MAF therapy [14]. Elevated Nagalase levels were found in individuals with ASD indicating immune dysfunction. Nagalase activity significantly decreased after treatment indicating therapeutic benefits. Improvements in language, social skills, and cognition were observed, which highlights the significance of nagalase and the potential benefits of Immunax for ASD.

Immunax Has Therapeutic Potential For Neurological Disorders

Numerous peer reviewed scientific studies suggest the potential benefits of Immunax in neurological disorders such as MS, Alzheimer’s, Parkinson’s, CFS, and ASD. However, it is important to note that the research is still evolving, and larger-scale clinical trials are needed. Individuals interested in this treatment should consult a qualified healthcare professional for personalized guidance.